{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:10:36Z","timestamp":1786367436629,"version":"build-2736575974"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:00:00Z","timestamp":1686182400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:00:00Z","timestamp":1686182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Diffuse large B-cell lymphoma is the most frequent histological subtype of NHL and the paradigm for the management of aggressive lymphoma. An excisional or incisional lymph node biopsy evaluated by an experienced hemopathologist is recommended to establish the diagnosis. Twenty years following its introduction, R-CHOP remains the standard first-line treatment. No modification of this scheme (increased chemotherapy dose intensity, new monoclonal antibodies, or the addition of immunomodulators or anti-target agents) has significatively improved the clinical outcomes, whereas therapy for recurrence or progression is evolving rapidly. The irruption of CART cells, polatuzumab vedotin, tafasitamab, and CD20\/CD3 bispecific antibodies are changing the natural history of relapsed patients and will challenge R-CHOP as the benchmark for newly diagnosed patients.<\/jats:p>","DOI":"10.1007\/s12094-023-03206-5","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T13:02:32Z","timestamp":1686229352000},"page":"2749-2758","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["SEOM-GOTEL clinical guidelines on diffuse large B cell lymphoma (2022)"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7541-9832","authenticated-orcid":false,"given":"Josep","family":"Gum\u00e0","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Palaz\u00f3n-Carri\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rueda-Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Sequero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram\u00f3n","family":"Garc\u00eda-Arroyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"G\u00f3mez-Codina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Llanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natividad","family":"Mart\u00ednez-Banaclocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Provencio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,8]]},"reference":[{"issue":"2","key":"3206_CR1","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1086\/321805","volume":"33","author":"CA Dykewicz","year":"2001","unstructured":"Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis. 2001;33(2):139\u201344.","journal-title":"Clin Infect Dis"},{"key":"3206_CR2","unstructured":"Red Espa\u00f1ola de Registros de C\u00e1ncer (REDECAN). Estimaciones de la incidencia del c\u00e1ncer en Espa\u00f1a, 2022. 2022."},{"issue":"Suppl 3","key":"3206_CR3","doi-asserted-by":"publisher","first-page":"iii90","DOI":"10.1093\/annonc\/mdq088","volume":"21","author":"R Marcos-Gragera","year":"2010","unstructured":"Marcos-Gragera R, Poll\u00e1n M, Chirlaque MD, Gum\u00e0 J, S\u00e1nchez MJ, Garau I. Attenuation of the epidemic increase in non-Hodgkin\u2019s lymphomas in Spain. Ann Oncol. 2010;21(Suppl 3):iii90-96.","journal-title":"Ann Oncol"},{"issue":"5","key":"3206_CR4","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/s12094-012-0813-3","volume":"14","author":"M Provencio","year":"2012","unstructured":"Provencio M, Sab\u00edn P, G\u00f3mez Codina J, Rueda A, Llanos M, Gum\u00e0 J, et al. Are there any significant variations in the clinical or histological presentation of lymphoid pathologies over the course of time in Spain? Clin Transl Oncol. 2012;14(5):386\u201390.","journal-title":"Clin Transl Oncol"},{"key":"3206_CR5","unstructured":"Red Espa\u00f1ola de Registros de C\u00e1ncer (REDECAN). Incidence and trends of haematological malignancies in Spain, 2002\u20132013. 2021."},{"key":"3206_CR6","unstructured":"Recomendaciones para el estudio histopatol\u00f3gico, inmunohistoqu\u00edmico, citogen\u00e9tico y molecular e informe diagn\u00f3stico de los procesos neopl\u00e1sicos linfoides. Consenso SEAP-SEHH-GOTEL. In: Rosell\u00f3 Sastre E, editors. Libro Blanco de la Anatom\u00eda Patol\u00f3gica en Espa\u00f1a. 7th ed. SEAP; 2021."},{"issue":"6769","key":"3206_CR7","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503\u201311.","journal-title":"Nature"},{"issue":"1","key":"3206_CR8","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275\u201382.","journal-title":"Blood"},{"issue":"4","key":"3206_CR9","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","volume":"37","author":"GW Wright","year":"2020","unstructured":"Wright GW, Huang DW, Phelan JD, Coulibaly ZA, Roulland S, Young RM, et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell. 2020;37(4):551\u201368.","journal-title":"Cancer Cell"},{"key":"3206_CR10","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., eds. WHO classification of tumours of haematopoietic and lymphoid tissues. Rev 4th ed. IARC; 2017."},{"issue":"27","key":"3206_CR11","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059\u201368.","journal-title":"J Clin Oncol"},{"key":"3206_CR12","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s00259-013-2623-4","volume":"41","author":"HJ Adams","year":"2014","unstructured":"Adams HJ, Kwee TC, de Keizer B, Fijnheer R, de Klerk JMH, Nievelstein RAJ. FDG PET\/CT for the detection of bone marrow involvement in diffuse large B-cell lymphoma: systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2014;41:565\u201374.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"14","key":"3206_CR13","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"International Non-Hodgkin's Lymphoma Prognostic Factors Project","year":"1993","unstructured":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med. 1993;329(14):987\u201394.","journal-title":"N Engl J Med"},{"issue":"14","key":"3206_CR14","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1200\/JCO.2009.26.2493","volume":"28","author":"M Ziepert","year":"2010","unstructured":"Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(14):2373\u201380.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3206_CR15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1056\/NEJM199807023390104","volume":"339","author":"TP Miller","year":"1998","unstructured":"Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate and high-grade non-Hodgkin\u2019s lymphoma. N Engl J Med. 1998;339(1):21\u20136.","journal-title":"N Engl J Med"},{"issue":"15","key":"3206_CR16","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1200\/JCO.2004.05.926","volume":"22","author":"TP Miller","year":"2004","unstructured":"Miller TP. The limits of limited stage lymphoma. J Clin Oncol. 2004;22(15):2982\u20134.","journal-title":"J Clin Oncol"},{"issue":"10216","key":"3206_CR17","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1016\/S0140-6736(19)33008-9","volume":"394","author":"V Poeschel","year":"2019","unstructured":"Poeschel V, Held G, Ziepert M, Witzens-Harig M, Holte H, Thurner L, et al. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet. 2019;394(10216):2271\u201381.","journal-title":"Lancet"},{"issue":"2","key":"3206_CR18","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1182\/blood-2017-07-793984","volume":"131","author":"T Lamy","year":"2018","unstructured":"Lamy T, Damaj G, Soubeyran P, Gyan E, Cartron G, Bouabdallah K, et al. R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma. Blood. 2018;131(2):174\u201381.","journal-title":"Blood"},{"issue":"3","key":"3206_CR19","doi-asserted-by":"publisher","first-page":"716","DOI":"10.3109\/10428194.2014.930853","volume":"56","author":"OO Odejide","year":"2015","unstructured":"Odejide OO, Cronin AM, Davidoff AJ, LaCasce AS, Abel GA. Limited stage diffuse large B-cell lymphoma: comparative effectiveness of treatment strategies in a large cohort of elderly patients. Leuk Lymphoma. 2015;56(3):716\u201324.","journal-title":"Leuk Lymphoma"},{"issue":"20","key":"3206_CR20","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1200\/JCO.2017.76.8093","volume":"36","author":"U D\u00fchrsen","year":"2018","unstructured":"D\u00fchrsen U, M\u00fcller S, Hertenstein B, Thomssen H, Kotzerke J, Mesters R, et al. Positron emission tomography-guided therapy of aggressive non-hodgkin lymphomas (PETAL): a multicenter, randomized phase iii trial. J Clin Oncol. 2018;36(20):2024\u201334.","journal-title":"J Clin Oncol"},{"issue":"26","key":"3206_CR21","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1200\/JCO.20.00999","volume":"38","author":"DO Persky","year":"2020","unstructured":"Persky DO, Li H, Stephens DM, Park SI, Bartlett NL, Swinnen LJ, et al. Positron emission tomography-directed therapy for patients with limited-stage diffuse large B-cell lymphoma: results of intergroup national clinical trials network study S1001. J Clin Oncol. 2020;38(26):3003\u201311.","journal-title":"J Clin Oncol"},{"issue":"11","key":"3206_CR22","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","volume":"12","author":"M Pfreundschuh","year":"2011","unstructured":"Pfreundschuh M, Kuhnt E, Trumper L, Osterborg A, Trneny M, Shepherd L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12(11):1013\u201322.","journal-title":"Lancet Oncol"},{"issue":"11","key":"3206_CR23","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1200\/JCO.2013.51.4505","volume":"32","author":"G Held","year":"2014","unstructured":"Held G, Murawski N, Ziepert M, Fleckenstein J, P\u00f6schel V, Zwick C, et al. Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. J Clin Oncol. 2014;32(11):1112\u20138.","journal-title":"J Clin Oncol"},{"issue":"18","key":"3206_CR24","doi-asserted-by":"publisher","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","volume":"23","author":"P Feugier","year":"2005","unstructured":"Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferm\u00e9 C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. J Clin Oncol. 2005;23(18):4117\u201326.","journal-title":"J Clin Oncol"},{"issue":"2","key":"3206_CR25","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","volume":"9","author":"M Pfreundschuh","year":"2008","unstructured":"Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9(2):105\u201316.","journal-title":"Lancet Oncol"},{"key":"3206_CR26","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(13)60313-X","volume":"381","author":"D Cunningham","year":"2013","unstructured":"Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet. 2013;381:1817\u201326.","journal-title":"Lancet"},{"issue":"6","key":"3206_CR27","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1470-2045(13)70122-0","volume":"14","author":"R Delarue","year":"2013","unstructured":"Delarue R, Tilly H, Mounier N, Petrella T, Salles G, Thieblemont C, et al. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. Lancet Oncol. 2013;14(6):525\u201333.","journal-title":"Lancet Oncol"},{"issue":"9806","key":"3206_CR28","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1016\/S0140-6736(11)61040-4","volume":"378","author":"C R\u00e9cher","year":"2011","unstructured":"R\u00e9cher C, Coiffier B, Haioun C, Molina TJ, Ferm\u00e9 C, Casasnovas O, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03\u20132B): an open-label randomised phase 3 trial. Lancet. 2011;378(9806):1858\u201367.","journal-title":"Lancet"},{"issue":"2","key":"3206_CR29","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/bjh.13273","volume":"169","author":"N Purroy","year":"2015","unstructured":"Purroy N, Bergua J, Gallur L, Prieto J, Lopez LA, Sancho JM, et al. Long-term follow-up of dose-adjusted EPOCH plus rituximab (DAEPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group. Br J Haematol. 2015;169(2):188\u201398.","journal-title":"Br J Haematol"},{"issue":"21","key":"3206_CR30","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1200\/JCO.18.01994","volume":"37","author":"NL Bartlett","year":"2019","unstructured":"Bartlett NL, Wilson WH, Jun SH, Hsi ED, Maurer MJ, Pederson LD, et al. Dose-Adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase iii intergroup trial alliance\/CALGB 50303. J Clin Oncol. 2019;37(21):1790\u20139.","journal-title":"J Clin Oncol"},{"issue":"31","key":"3206_CR31","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1200\/JCO.2017.73.3402","volume":"35","author":"U Vitolo","year":"2017","unstructured":"Vitolo U, Trnen\u00fd M, Belada D, Burke JM, Carella AM, Chua N, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. J Clin Oncol. 2017;35(31):3529\u201337.","journal-title":"J Clin Oncol"},{"issue":"4","key":"3206_CR32","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trn\u011bn\u00fd M, Sharman JP, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022;386(4):351\u201363.","journal-title":"N Engl J Med"},{"key":"3206_CR33","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht C, Glass B, Mounier N, Gill DS, Linch DC, Trneny M, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:4184\u201390.","journal-title":"J Clin Oncol"},{"key":"3206_CR34","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","volume":"32","author":"M Crump","year":"2014","unstructured":"Crump M, Kuruvilla J, Couban S, MacDonald DA, Kukreti V, Kouroukis CT, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY12. J Clin Oncol. 2014;32:3490\u20136.","journal-title":"J Clin Oncol"},{"issue":"7","key":"3206_CR35","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022;386(7):640\u201354.","journal-title":"N Engl J Med"},{"issue":"7","key":"3206_CR36","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa2116596","volume":"386","author":"MR Bishop","year":"2022","unstructured":"Bishop MR, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N, et al. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. N Engl J Med. 2022;386(7):629\u201339.","journal-title":"N Engl J Med"},{"issue":"10343","key":"3206_CR37","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"M Kamdar","year":"2022","unstructured":"Kamdar M, Solomon SR, Arnason J, Johnston P, Glass B, Bachanova V, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022;399(10343):2294\u2013308.","journal-title":"Lancet"},{"issue":"2","key":"3206_CR38","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1200\/JCO.19.00172","volume":"38","author":"LH Sehn","year":"2020","unstructured":"Sehn LH, Herrera AF, Flowers CR, Kamdar LK, McMillan A, Hertzberg M, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020;38(2):155\u201365.","journal-title":"J Clin Oncol"},{"issue":"7","key":"3206_CR39","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","volume":"21","author":"G Salles","year":"2020","unstructured":"Salles G, Duell J, Gonzalez Barca E, Tournilhac O, Jurczak W, Liberati AM, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020;21(7):978\u201388.","journal-title":"Lancet Oncol"},{"issue":"1","key":"3206_CR40","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol. 2019;20(1):31\u201342.","journal-title":"Lancet Oncol"},{"issue":"10","key":"3206_CR41","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","volume":"22","author":"SJ Schuster","year":"2021","unstructured":"Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22(10):1403\u201315.","journal-title":"Lancet Oncol"},{"issue":"10254","key":"3206_CR42","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839\u201352.","journal-title":"Lancet"},{"issue":"31","key":"3206_CR43","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.1200\/JCO.2014.55.7561","volume":"32","author":"CA Thompson","year":"2014","unstructured":"Thompson CA, Ghesquieres H, Maurer MJ, Cerhan JR, Biron P, Ansell SM, et al. Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma. J Clin Oncol. 2014;32(31):3506\u201312.","journal-title":"J Clin Oncol"},{"issue":"34","key":"3206_CR44","doi-asserted-by":"publisher","first-page":"3993","DOI":"10.1200\/JCO.2015.62.0229","volume":"33","author":"TC El-Galaly","year":"2015","unstructured":"El-Galaly TC, Jakobsen LH, Hutchings M, Brown PN, Nilsson-Ehle H, Sz\u00e9kely E, et al. Routine imaging for diffuse large B-cell lymphoma in first complete remission does not improve post-treatment survival: a Danish-Swedish population-based study. J Clin Oncol. 2015;33(34):3993\u20138.","journal-title":"J Clin Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-023-03206-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-023-03206-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-023-03206-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T11:15:43Z","timestamp":1692011743000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-023-03206-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,8]]},"references-count":44,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["3206"],"URL":"https:\/\/doi.org\/10.1007\/s12094-023-03206-5","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,8]]},"assertion":[{"value":"18 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JG reports Advisory Board from\u00a0Incyte Biosciences and\u00a0Kite-Gilead; Other from\u00a0Roche. AR reports Advisory y Honoraria Speaker from Roche, BMS, MSD, Takeda, Merck and Gilead. VC reports Advisory Board from Roche, BMS, Astrazeneca and BOEHRINGER INGELHEIM; Personal Feels from Roche, BMS, MSD, Astrazeneca, Takeda, Lilly and BOEHRINGER INGELHEIM; Speaker from BMS, MSD, Astrazeneca, Takeda, Pfizer and BOEHRINGER INGELHEIM. ML reports Advisory Board from\u00a0INCYTE; Speaker from\u00a0ROCHE. MPP reports Advisory Board and Speaker from Roche and Takeda; Advisory Board from Incyte. NPC, NMB, JGC, RGA, SS have nothing to disclose. The current manuscript has been drafted in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This is not a study with patients or animals. It is a Guidelines and, therefore, it does not require approval by an\nethical committee or informed consent from the patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval (Research involving human participants and\/or animals); Informed consent"}}]}}